In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality

Michelle D Kelsey; L Kristin Newby

doi:10.7326/J22-0003

In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality

Ann Intern Med. 2022 Mar;175(3):JC26. doi: 10.7326/J22-0003. Epub 2022 Mar 1.

Authors

Michelle D Kelsey¹, L Kristin Newby¹

Affiliation

¹ Duke University, Durham, North Carolina, USA (M.D.K., L.K.N.).

PMID: 35226528
DOI: 10.7326/J22-0003

Abstract

Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10:CD013650. 34693515.

Publication types

Comment

MeSH terms

Cardiovascular Diseases* / mortality
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / mortality
Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use
Glucagon-Like Peptide 1 / agonists
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Glucagon-Like Peptide 1